Search results
Results from the WOW.Com Content Network
A British Approved Name (BAN) is the official, non-proprietary, or generic name given to a pharmaceutical substance, as defined in the British Pharmacopoeia (BP). [1] The BAN is also the official name used in some countries around the world, because starting in 1953, proposed new names were evaluated by a panel of experts from WHO in conjunction with the BP commission to ensure naming ...
The 1699 Edinburgh Pharmacopoeia. A pharmacopoeia, pharmacopeia, or pharmacopoea (from the obsolete typography pharmacopœia, meaning "drug-making"), in its modern technical sense, is a book containing directions for the identification of compound medicines, and published by the authority of a government or a medical or pharmaceutical society. [1]
USP 800 is an example of a publication created by the United States Pharmacopeia. Prescription and over-the-counter medicines available in the United States must, by federal law, meet USP-NF public standards, where such standards exist.
Pharmacopoeia Britannica: British Pharmacopoeia Ph.Eur. Pharmacopoeia Europaea: European Pharmacopoeia Ph.Int. Pharmacopoeia Internationalis: International Pharmacopoeia pig./pigm. pigmentum: paint p.m. post meridiem: evening or afternoon p.o. per os: by mouth or orally AMA style avoids use of this abbreviation (spell out "orally") ppt ...
British Approved Names (BANs) are devised or selected by the British Pharmacopoeia Commission (BPC), and published by the Health Ministers, on the recommendation of the Commission on Human Medicines, to provide a list of names of substances or articles referred to in Section 100 of the Medicines Act 1968. BANs are short, distinctive names for ...
Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs.In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. [1]
General index: prepared from over 175,000 entries it includes approved names, synonyms and chemical names; a separate Cyrillic section lists non-proprietary and proprietary names in Russian and Ukrainian. Digital versions include an additional 1,000 drug monographs, 100,000 preparation names, and 5,000 manufacturers.
For example, under a 3-tier formulary, the first tier typically includes generic drugs with the lowest cost sharing (e.g., 10% coinsurance), the second includes preferred brand-name drugs with higher cost sharing (e.g., 25%), and the third includes non-preferred brand-name drugs with the highest cost-sharing (e.g., 40%).